Industry news that matters to you.  Learn more

Archives for June 2012

RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration

RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech’s proprietary antibody arrays for the high-throughput detection and analysis of protein biomarkers in biological samples. The service program will target academic and industrial research clients having a need for fully quantifiable biomarker analysis.

NCBiotech Weighs Personalized Medicine Sector

The North Carolina Biotechnology Center has approved a $100,000 grant to explore the state’s readiness for a Center of Innovation (COI) to help capitalize on the growing field of personalized medicine.

KineMed Announces Biomarker Discovery Collaboration with GSK

KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.

Decoding DNA Finds Breast Tumor Signatures that Predict Treatment Response

Decoding the DNA of patients with advanced breast cancer has allowed scientists to identify distinct cancer “signatures” that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.

Mayo Medical Laboratories and Atherotech Diagnostics Lab to Offer Critical Diagnostics’ ST2 Test

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that two major reference laboratories — Mayo Medical Laboratories and Atherotech Diagnostics Lab — will offer the company’s Presage ST2 test. The Presage ST2 Assay was recently cleared by the U.S. Food and Drug Administration for use in assessing the prognosis of patients diagnosed with chronic heart failure.